BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37914247)

  • 1. [Clinical characteristics and management of children, adolescents, and young adults with Philadelphia chromosome-negative myeloproliferative neoplasms].
    Sugimoto Y
    Rinsho Ketsueki; 2023; 64(10):1314-1325. PubMed ID: 37914247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
    Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
    Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
    Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
    BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
    Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
    Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy.
    Sant'Antonio E; Borsani O; Camerini C; Botta C; Santoro M; Allegra A; Siragusa S
    Blood Rev; 2022 Mar; 52():100903. PubMed ID: 34742614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloproliferative neoplasms in adolescents and young adults.
    Amerikanou R; Lambert J; Alimam S
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101374. PubMed ID: 36333071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mean platelet volume and risk of thrombotic and bleeding complications in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Krashin E; Cohen O; Pereg D; Lishner M; Leader A
    Blood Coagul Fibrinolysis; 2018 Apr; 29(3):288-293. PubMed ID: 29474204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms.
    Seguro FS; Teixeira LLC; da Rosa LI; da Silva WF; Nardinelli L; Bendit I; Rocha V
    J Thromb Thrombolysis; 2020 May; 49(4):667-672. PubMed ID: 31898273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Philadelphia-negative myeloproliferative neoplasms among Kuwaiti Nationals.
    Alshemmari S; Almazyad M; Alwehaib A; Ameen R
    Cancer Med; 2021 Jan; 10(1):365-371. PubMed ID: 33280271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome].
    Melikyan AL; Subortseva IN; Koloshejnova EA; Gilyazitdinova EA; Shashkina KS; Gorgidze LA; Tratsevskaya ZV; Margolin OV
    Ter Arkh; 2019 Jul; 91(7):93-99. PubMed ID: 32598741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
    Robinson SE; Harrison CN
    Br J Haematol; 2020 May; 189(4):625-634. PubMed ID: 32150650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Sankar K; Stein BL; Rampal RK
    Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
    Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
    Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.
    Hochman MJ; Smith BD; Karantanos T; Braunstein EM; Gojo I; Jain T; Streiff MB; Moliterno AR; DeZern AE
    Int J Hematol; 2023 Mar; 117(3):456-462. PubMed ID: 36181657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
    De Stefano V; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; Rossi E; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Finazzi G; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Rapezzi D; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Isfort S; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Rambaldi A; Barbui T
    Blood; 2020 Jan; 135(5):381-386. PubMed ID: 31869407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.
    Casini A; Fontana P; Lecompte TP
    J Thromb Haemost; 2013 Jul; 11(7):1215-27. PubMed ID: 23601811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.
    Kucine N
    Curr Hematol Malig Rep; 2020 Apr; 15(2):141-148. PubMed ID: 32172359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.